Perioperative treatment with sacituzumab govitecan (Trodelvy) and pembrolizumab (Keytruda) has achieved promising clinical complete response rates in patients with muscle-invasive bladder cancer. This combination made it possible to preserve the bladder in almost 40% of patients. The study was conducted in San Francisco and was featured on MedPage Today. It is an organ-sparing strategy that appears to be a promising alternative to standard methods. Treatment included the administration of drugs in the perioperative period. The main finding is the high rate of preservation of bladder function when achieving a complete response.